Use of recombinant human erythropoietin (r-HuEPO) in a Jehovah's Witness ³
refusing transfusion of blood products: case report [see comments]. Á Koestner JA. Nelson LD. Morris JA Jr. Safcsak K. Journal of Trauma. 30(11):1406-8, 1990 Nov. Recombinant human erythropoietin (r-HuEPO) administration to a Jehovah's witness refusing blood transfusions increased her nadir packed cell volume from 13% to 37% and reticulocyte count from 2% to 17.7%. R-HuEPO may provide an alternative safe and effective therapy in life-threatening anemia when blood transfusions are unacceptable to the patient. * Á
Original Text by Clifford R. Wheeless, III, MD.
|
